Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases

Journal of Neuro-Oncology

Volumn 127, Issue 3, 2016, Pages 607-615

  Wolf, Amparo ^a   Zia, Sayyad ^a   Verma, Rashika ^a   Pavlick, Anna ^a   Wilson, Melissa ^a   Golfinos, John G ^a   Silverman, Joshua S ^a   Kondziolka, Douglas ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BRAF inhibitors; BRAF mutation; Brain metastasis; Metastatic melanoma; Stereotactic radiosurgery

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN;

ADULT; AGE; ANALYSIS; ARTICLE; BRAF GENE; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN RADIATION; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; CRANIOTOMY; DISEASE CONTROL; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RECURSIVE PARTITIONING ANALYSIS; SEX DIFFERENCE; STEREOTACTIC RADIOSURGERY; SURVIVAL PREDICTION; SURVIVAL RATE; SYSTEMIC DISEASE; TUMOR BLEEDING; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; WHOLE BRAIN RADIATION THERAPY; AGED; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STAGING; FOLLOW UP; GENETICS; MELANOMA; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROGNOSIS; RADIOSURGERY; SECONDARY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RADIOSURGERY; SURVIVAL RATE;

EID: 84957575093     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2072-6     Document Type: Article

References (35)

1. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11–20
2. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, Shapiro R, Berman R, Darvishian F, Hernando E, Pavlick A, Osman I (2011) Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117:1711–1720
3. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293–1300
4. Khan KH, Goody RB, Hameed H, Jalil A, Coyle VM, McAleer JJ (2012) Metastatic melanoma: a regional review and future directions. Tumori 98:575–580
5. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012
6. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213–1218
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365
10. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714
11. Dzienis MR, Atkinson VG (2014) Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res 24:349–353
12. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087–1095
13. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:611–621
14. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, Kirkwood JM, Tarhini A, Moschos S, Lunsford LD (2011) Outcome predictors of Gamma Knife surgery for melanoma brain metastases: clinical article. J Neurosurg 114:769–779
15. Neal MT, Chan MD, Lucas JT, Jr., Loganathan A, Dillingham C, Pan E, Stewart JHT, Bourland JD, Shaw EG, Tatter SB, Ellis TL(2014) Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg 82:1250–1255
16. Lavine SD, Petrovich Z, Cohen-Gadol AA, Masri LS, Morton DL, O’Day SJ, Essner R, Zelman V, Yu C, Luxton G, Apuzzo ML (1999) Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 44:59–64; discussion 64–56
17. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL (2008) Stereotactic radiosurgery for patients with “radioresistant” brain metastases. Neurosurgery 62(Suppl 2):790–801
18. Christopoulou A, Retsas S, Kingsley D, Paddick I, Lindquist C (2006) Integration of gamma knife surgery in the management of cerebral metastases from melanoma. Melanoma Res 16:51–57
19. Gaudy-Marqueste C, Regis JM, Muracciole X, Laurans R, Richard MA, Bonerandi JJ, Grob JJ (2006) Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 65:809–816
20. Selek U, Chang EL, Hassenbusch SJ 3rd, Shiu AS, Lang FF, Allen P, Weinberg J, Sawaya R, Maor MH (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59:1097–1106
21. Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve DC (2015) Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 123:395–401
22. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Parker EC, Ott PA, Pavlick AC (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411–416
23. Rompoti N, Schilling B, Livingstone E, Griewank K, Hillen U, Sauerwein W, Pottgen C, Stuschke M, Schadendorf D, Zimmer L (2013) Combination of Braf inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 31:3844–3845
24. Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG (2015) LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 122:121–126
25. Kondziolka D, Cooper BT, Lunsford DL, Silverman J (2015) Development, implementation, and use of a local and global clinical registry for neurosurgery. Big Data 3:80–90
26. Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, Kirkwood J, Lunsford LD (2007) Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60:471–481; discussion 481–472
27. Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM (2015) Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Cancer Med 4:1205–1213
28. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977
29. Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G, Muller-Brenne T, Bauch J, Eich HT, Grabbe S, Schadendorf D, Schuler G, Keikavoussi P, Semrau S, Fietkau R, Distel LV, Heinzerling L (2015) Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 26:1238–1244
30. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF (2012) Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342:33–40
31. Dasgupta T, Haas-Kogan DA, Yang X, Olow A, Yang DX, Gragg A, Orloff LA, Yom SS (2013) Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs 31:1136–1141
32. Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ (2015) Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res 25:75–79
33. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R (2011) BRAF mutations in advanced cancers: clinical characteristics and outcomes. Plos One 6:e25806
34. Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, Scolyer RA (2013) BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 133:509–517
35. Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, Richard MA, Regis J, Grob JJ (2014) On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 25:2086–2091